Brief: Atossa Therapeutics Streamlines Evangeline Breast Cancer Clinical Trial To Prioritize For 2026 NDA-Enabling Activities
06/10/2025 13:24
Oct 6 (Reuters) - Atossa Therapeutics Inc ATOS.O: ATOSSA THERAPEUTICS STREAMLINES EVANGELINE BREAST CANCER CLINICAL TRIAL TO PRIORITIZE FOR 2026 NDA-ENABLING ACTIVITIES ATOSSA THERAPEUTICS INC - CHANGES EXPECTED TO REDUCE STUDY COSTS AND ACCELERATE READOUTS ATOSSA THERAPEUTICS INC - FOCUSES ON NDA-ENABLING ACTIVITIES FOR INVESTIGATIONAL (Z)-ENDOXIFEN IN 2026 ATOSSA THERAPEUTICS INC - EVANGELINE STUDY PATIENT TOTAL REDUCED TO 40-65 ATOSSA THERAPEUTICS - NO CHANGE TO PATIENT SAFETY DATA COLLECTION OR DATA SAFETY MONITORING COMMITTEE OVERSIGHT BY THIS AMENDMENT Source text: ID:nPn5DxbwHa Further company coverage: ATOS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary